申请人:MCW Research Foundation
公开号:US06596769B2
公开(公告)日:2003-07-22
20-HETE agonists and antagonists are disclosed along with therapeutic applications. In a preferable form of the invention, the 20-HETE agonists are selected from the group consisting of 21-hydroxyheneicosa-5(Z),8(Z),11(Z),14(Z)-tetraenoic acid, 20-hydroxyeicosa-5(Z),4(Z)-dienoic acid and 20-,21-dimethyl 20-HETE. Preferable 20-HETE antagonists include 5(S)-HETE, 15(S)-HETE, 19(S)-HETE, 19-hydroxynonadeca-5(Z),8(Z),11(Z),14(Z)-tetraenoic acid and 20-hydroxyeicosa 6(Z),15(Z)-dienoic acid.
本发明揭示了20-HETE激动剂和拮抗剂以及其治疗应用。在本发明的一种优选形式中,20-HETE激动剂被选择自由21-羟基十九烷-5(Z),8(Z),11(Z),14(Z)-四烯酸、20-羟基二十碳五烯-5(Z),4(Z)-二烯酸和20-,21-二甲基20-HETE的组中。优选的20-HETE拮抗剂包括5(S)-HETE、15(S)-HETE、19(S)-HETE、19-羟基十九烷-5(Z),8(Z),11(Z),14(Z)-四烯酸和20-羟基二十碳六烯-6(Z),15(Z)-二烯酸。